secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060219
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics reports Q3 net loss of $57.5M; Phase 3 acromegaly study met all endpoints
--------------------------------------------------------------------------------

- Phase 3 PATHFNDR-1: 83% paltusotine vs 4% placebo maintained IGF-1 ≤1xULN (p<0.0001); all secondary endpoints met.
- Phase 3 PATHFNDR-2 enrollment completed (112 participants); topline data expected Q1 2024.
- Initial Phase 2 data for paltusotine in carcinoid syndrome expected December 2023; NDA submission planned for 2024.
- Net loss $57.5M vs $41.9M YoY; R&D expenses $43.8M (up $11.8M); G&A $15.5M (up $3.6M).
- Cash $554.7M as of Sep 30, 2023; $350M public offering completed; cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/0000950170-23-060219-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023060219/crnx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060219

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer